|
業務類別
|
Biotechnology |
|
業務概覽
|
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. |
| 公司地址
| 1167 Massachusetts Avenue, Arlington, MA, USA, 02476 |
| 電話號碼
| +1 781 996-5252 |
| 傳真號碼
| +1 781 642-0399 |
| 公司網頁
| https://www.kalarx.com |
| 員工數量
| 6 |
| Mr. Avi Minkowitz |
Director, Chief Executive Officer and Chief Financial Officer |
-- |
05/02/2026 |
| Ms. Mary Reumuth |
Treasurer, Corporate Secretary and Principal Accounting Officer |
-- |
05/02/2026 |
|
|
| Mr. Yonatan C. Colman |
Independent Director |
15/04/2026 |
| Mr. Chaim D. Berger |
Independent Director |
15/04/2026 |
| Mr. Avi Minkowitz |
Director, Chief Executive Officer and Chief Financial Officer |
05/02/2026 |
| Mr. Hillel D. Posen |
Independent Director |
15/04/2026 |
| Mr. Brendan Purdy |
Independent Director |
15/04/2026 |
|
|
|
|
